Compliance with Highly Active Antiretroviral Therapy (HAART) does not Prevent Human Papilloma Virus (HPV) Related Cancers in Women Infected with Human Immunodeficiency Virus (HIV)
DOI:
https://doi.org/10.17140/GOROJ-6-149Keywords:
Human immunodeficiency virus (HIV), Cancer, Human papilloma virus(HPV), Women, AIDS, Highly active anti-retroviral therapy (HAART)Abstract
Introduction
Cancer is one of the leading causes of death in people with human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), due to behavioral choices and overlapping risk factors.
Aim
The purpose of this report is to determine the long-term incidence of human papilloma virus (HPV)-associated cancer in women with pre-invasive cervical neoplasia, and compliance with medication and cancer screening recommendations.
Methods
HIV-infected women diagnosed with pre-invasive cervical neoplasia and an HPV-associated malignancy between 1995-2008 were identified. Data collected includes: demographics, HIV treatment/response, malignancy treatment/response, other healthcare utilization, use of health navigators, and compliance.
Results
Seventy one subjects were identified with HIV infection, cervical dysplasia, and at least ten years’ follow-up. 17/71 (24%) were identified with an HPV-related malignancy. The mean age of those diagnosed with HPV-related malignancy was 39-years. Malignancies included: Cervix-9, Vulva-7, Anal-4, Vagina-3, Uretha/Bladder-2, Oropharyngeal-3. Eight also had in-situ neoplasms: Cervix-4, Vulva-3, Oropharyngeal-1. Four subjects had 3 separate malignancies, and two others had 2 malignancies. Compliance with HAART correlated strongly with immunocompetence, response to therapy, use of patient navigators, and survival. Sixty out of saventy one (84.5%) subjects underwent screening mammography, 57/71 (80.3%) underwent colonoscopy, and 67/71 (94.3%) underwent pap smear testing. Compliance with screening compared favorably with the general population, and overall survival was similar.
Discussion and Conclusion
The long-term incidence and mortality from cancer in women with HIV and cervical dysplasia appears to be comparable to that seen in the general population, with the possible exception of oropharyngeal cancers. Compliance with cancer screening recommendations appears to be higher than in the general population. This suggests that structured primary care programs for HIV-infected women are effective in prevention/early diagnosis of cancer. Standardized screening programs for oropharyngeal cancers should be considered in this population.
References
Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): Trends since 2000. AIDS. 2014; 28: 1181-1191. doi: 10.1097/ QAD.0000000000000222
Trickey A, May MT, Vehreschild J, et al. Cause-specific mortality in HIV-positive patients who survived ten years after starting anti-retroviral therapy. PLoS One. 2016; 11(8): e0160460. doi: 10.1371/ journal.pone.0160460
Park LS, Tate JP, Sigel K, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. AIDS. 2016; 30(11): 1795-1806. doi: 10.1097/ QAD.0000000000001112
Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among people with AIDS in the United States. Cancer. 2011; 117(5): 1089-1096. doi: 10.1002/cncr.25547
Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103(9): 753-762. doi: 10.1093/jnci/djr076
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, Immu-nodeficiency, Viral replication and the risk of cancer. Cancer Epide-miol Biomarkers Prev. 2011; 20(12): 2551-2559. doi: 10.1158/1055- 9965.EPI-11-0777
Riedel DJ, Rositch AF, Redfield RR. Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining can-cers in HIV-infected individuals. Infect Agent Cancer. 2015; 10: 38. doi: 10.1186/s13027-015-0033-x
Park LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: A meta-analysis. AIDS. 2016; 30(2): 273- 291. doi: 10.1097/QAD.0000000000000922
Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people in-fected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123: 187-194. doi: 10.1002/ijc.23487
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus–associated cancers among persons with AIDS. J Natl Cancer Inst. 2009; 101(16): 1120-1130. doi: 10.1093/ 9 Robinson WR, et al jnci/djp205
Marcus JL, Chao C, Leyden WA, et al. Survival Among HIV-in-fected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015; 24(8): 1167-1173. doi: 10.1158/1055-9965.EPI-14-1079
Abraham AG, Strickler HD, Jing Y, et al. Invasive cervical can-cer risk among HIV-infected women: A North American multi-cohort collaboration prospective study. J Acquir Immune Defic Syndr. 2013; 62(4): 405-413. doi: 10.1097/QAI.0b013e31828177d7
Louisiana Breast and Cervical Cancer Health Program. Web site. http://lbchp.org/breast-cancer/. 2017. Accessed April 17, 2019.
Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the im-pact of antiretroviral therapy: A 20-year cohort study. AIDS. 2009; 23(1): 41-50. doi: 10.1097/QAD.0b013e328317cc2d
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009; 23(17): 2337-2345. doi: 10.1097/QAD.0b013e3283319184
Clark RA, Mirabelli R, Shafe J, Broyles S, Besch L, Kissinger P. The new orleans HIV outpatient program patient experience with hurricane katrina. J La State Med Soc. 2007; 159(5): 276, 278-279, 281.
Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS in the United States. Arch Intern Med. 2010; 170(15): 1337-1345. doi: 10.1001/archinternmed.2010.253
Adler DH, Wallace M, Bennie T, et al. Cumulative impact of HIV and multiple concurrent human papillomavirus infections on the risk of cervical dysplasia. Adv Virol. 2016; 2016: 7310894. doi: 10.1155/2016/7310894
Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000; 283(8): 1031-1037. doi: 10.1001/jama.283.8.1031
Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immuno-deficiency virus-positive women. J Natl Cancer Inst. 2005; 97: 577- 586. doi: 10.1093/jnci/dji073
Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA. 2005; 293(12): 1471-1476. doi: 10.1001/jama.293.12.1471
Massad LS, Pierce CB, Minkoff H, et al. Long-term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse af-ter abnormal cytology: Impact of HIV infection. Int J Cancer. 2014; 134(8): 1854-1861. doi: 10.1002/ijc.28523 Brief Research Report | Volume 6 | Number 1|
Massad LS, Seaberg EC, Watts DH, et al. Low incidence of invasive cervical cancer among HIV-infected US women in a pre-vention program. AIDS. 2004; 18: 109-113.
Robinson W, Freeman D. Improved outcome of cervical neo-plasia in HIV-infected women in the highly active antiretroviral therapy (HAART) era. AIDS Patient Care STDS. 2002; 16(2): 61-65.
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014; 50(5): 380-386. doi: 10.1016/j.oraloncology.2013.12.019
Beachler DC, Weber KM, Margolick JB, et al. Risk factors for Submit your article to this journal | https://openventio.org/submit-manuscript/ Brief Research Report | Volume 6 | Number 1| Robinson WR, et al oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 122-133. doi: 10.1158/1055-9965.EPI-11-0734
Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011; 8(3): 142-152. doi: 10.1007/s11904-011- 0085-5
Tyerman Z, Aboulafia DM. Review of screening guidelines for non-AIDS-defining malignancies: Evoking issues in the era of highly active antiretroviral therapy. AIDS Rev. 2012; 14(1): 3-16.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gynecology and Obstetrics Research (GOR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
